Customizing treatment to patient populations

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue SUPPL. 1, 2007, Pages

  Brown Jr , Robert S ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAMIDINE; RIBAVIRIN; VIRUS RNA;

AFRICAN AMERICAN; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; LIVER FIBROSIS; LOW DRUG DOSE; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; RNA ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 33846417320     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0693     Document Type: Article

References (33)

1. Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965
2. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982
3. Hadziyannis SJ et al. (2004) Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355
4. Neumann AU et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103-107
5. Ferenci P et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol 43: 425-433
6. Sanchez-Tapias JM et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastorenterology 131: 451-460
7. Hopkins S et al. (2006) Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 7: 248-254
8. Fuster D et al. (2006) Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther 11: 473-482
9. Dalgard O et al. (2004) Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 40: 1260-1265
10. von Wagner M et al. (2005) Peginterferon-α2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522-527
11. Mangia A et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 325: 2609-2617
12. Shiffman ML (2006) Peginterferon alfa-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. Presented at 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26-30, Vienna, Austria
13. Berg T et al. (2006) Individualized treatment strategy with peginterferon alfa-2b (PEG-IFN ALFA) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients. Presented at: 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26-30, Vienna, Austria
14. Jacobson IM et al. (2005) Weight-based ribavirin dosing increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, a US community based trial. Hepatology 42 (Suppl 1): 749A
15. Brown RS. Customizing treatment to patient populations. Presented at Treating Hepatitis C in Difficult-to-Treat Patients and Special Populations: 2006, 22 May, Los Angeles, CA
16. Brown RS et al. (2006) Differences in treatment outcomes to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. J Hapatol 44 (Suppl 2): S20
17. Afdhal N et al. (2006) The effect of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: Results from the WIN-R trial. Gastroenterology 140 (Suppl 2): P120
18. Benhamou Y et al. (2006) The safety and efficacy of viramidine plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV: Phase 3 results. J Hepatol 44 (Suppl 2): S273
19. HCV Meta-analysis Working Group et al. (2005) Efficacy of weight-based PEG-IFN alfa-2b vs. fixed dose PEG-IFN alfa-2a + ribavirin regimens in treatment-naïve chronic HCV patients: A cumulative meta-analysis of retrospective data from 6 clinic sites. Hepatology 42 (Suppl 1): 671A
20. Ferenci P (2003) Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: Just a marketing 'gag'? Dig Liver Dis 35: 601-606
21. Meyer-Wyss B et al. (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hapat 13: 457-465
22. Muir AJ et al. (2004) Peginterferon alfa-2b ban ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265-2271
23. Jeffers LJ et al. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708
24. Conjeevaram HS et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477
25. Jacobson I et al. (2004) Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans (AA) compared to flat dose ribavirin with peginterferon alfa-2B combination therapy. Hepatology 40 (Suppl 1): 125
26. Zeuzem S et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999
27. Teuber G et al. (2003) Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Gastroenterology 124 (Suppl 1): A768
28. Jacobson IM et al. (2003) Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results. Gastroenterology 124 (Suppl 1): A714
29. Sulkowski M et al. (2003) Pharmacokinetics, pharmacodynamics, and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving Peginterferon (40KD) alfa-2a (Pegasys). Gastroenterology 124 (Suppl 1): A702-703
30. Lawitz EJ et al. (2003) Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 124 (Suppl 1): A783-784
31. Gross JB et al. (2005) Double-dose peginterferon alfa-2b plus weight-based ribavirin for re-treatment of African-American non-responders with hepatitis C. Gastroenterology 123 (Suppl 2): A-684
32. Shiffman ML et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015-1023
33. Leevy C et al. (2004) Interim results of a pilot study of the combination of type 1 (IFN Alfacon 1) and type 2 (IFN Gamma 1B) interferons in chronic hepatitis C patients who have failed to respond to peg-interferon alfa 2a plus ribavirin. Hepatology 40 (Suppl 4): 102A